This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, L. H.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2006, p. 142-164, Vol. 19, No. 1
0893-8512/06/$08.00+0     doi:10.1128/CMR.19.1.142-164.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Prospects for Vaccine Prevention of Meningococcal Infection

Lee H. Harrison*

Infectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania

Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.

* Mailing address: Infectious Diseases Epidemiology Research Unit, 521 Parran Hall, 130 Desoto St., University of Pittsburgh, Pittsburgh, PA 15261. Phone: (412) 624-3137. Fax: (412) 624-2256. E-mail: lharriso{at}edc.pitt.edu.

Clinical Microbiology Reviews, January 2006, p. 142-164, Vol. 19, No. 1
0893-8512/06/$08.00+0     doi:10.1128/CMR.19.1.142-164.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sorhouet Pereira, C., Regueira, M., Mollerach, M. (2008). PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 57: 338-342 [Abstract] [Full Text]  
  • Lee, H. S. W., Boulton, I. C., Reddin, K., Wong, H., Halliwell, D., Mandelboim, O., Gorringe, A. R., Gray-Owen, S. D. (2007). Neisserial Outer Membrane Vesicles Bind the Coinhibitory Receptor Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 1 and Suppress CD4+ T Lymphocyte Function. Infect. Immun. 75: 4449-4455 [Abstract] [Full Text]  
  • Fusco, P. C., Farley, E. K., Huang, C.-H., Moore, S., Michon, F. (2007). Protective Meningococcal Capsular Polysaccharide Epitopes and the Role of O Acetylation. CVI 14: 577-584 [Abstract] [Full Text]  
  • Nelson, C. B., Birmingham, M., Costa, A., Daviaud, J., Perea, W., Kieny, M.-P., Tarantola, D. (2007). Preparedness for Infectious Threats: Public-Private Partnership to Develop an Affordable Vaccine for an Emergent Threat: The Trivalent Neisseria meningitidis ACW135 Polysaccharide Vaccine. Am. J. Public Health 97: S15-S22 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»